| Date | Title | Description |
| 17.03.2026 | iDEL Therapeutics Raises €9M in Seed Funding | iDEL Therapeutics, a Dortmund, Germany-based cancer therapeutics company, raised €9M in Seed funding.
The round was led by BiomedVC with participation from NRW.Venture, Gründerfonds Ruhr and the KHAN Technology Transfer Fund II.
The company... |
| 17.03.2026 | German BioTech iDEL Therapeutics lands €9 million to develop cancer therapeutics platform | Dortmund-based iDEL Therapeutics announced the closing of a €9 million Seed financing, to develop a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells.
The financing was led by BiomedVC with particip... |
| 17.03.2026 | iDEL Therapeutics: €9 Million Raised To Advance Cytosolic Cancer Drug Delivery Platform | iDEL Therapeutics, a newly launched German biotech company, has raised €9 million in seed financing to advance a novel oncology platform that delivers therapeutics directly into the cytosol of tumor cells.
The funding round was led by Biome... |
| 24.12.2025 | T-CURX: $20 Million Series A First Closing Raised To Advance Non-Viral CAR-T Pipeline And In Vivo Platform | T-CURX GmbH said it has completed the first closing of a $20 million (€17.7 million) Series A financing to accelerate the clinical development of its non-viral CAR-T programs in acute myeloid leukemia and solid tumors, while advancing propr... |
| 21.12.2025 | T-CURX Secures $20M Series A to Advance Non-Viral CAR-T Cancer Therapies | German biotech T-CURX closed a $20 million Series A funding round. The Würzburg-based company will accelerate clinical development of its non-viral CAR-T cell therapies. These innovative treatments target acute myeloid leukemia (AML) and so... |
| 17.12.2025 | German startup T-CURX secures €17.7 million to support development of new cancer treatments | Würzburg-based T-CURX today announces the first closing of a €17.7 million Series A to accelerate clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary ... |
| 17.12.2025 | T-Curx Raises $20M in Series A First Closing | T-Curx, a Würzburg, Germany-based biotech company, raised $20M in Series A financing
The round was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, as additional investors along with existing and ne... |
| 18.09.2024 | Immunos Therapeutics raises USD11 million |
ImmunOs’ lead program IOS-1002 is currently tested in a Phase Ia dose escalation clinical trial as a monotherapy and in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). IOS-1002 is a novel, multifunctional immunotherapy a... |
| 20.09.2023 | TOLREMO therapeutics Completes USD 39 Million Series A Financing Round | |
| 12.09.2022 | What the biotech bear market means for start-ups | |
| 07.06.2022 | ImmunOs Therapeutics raises $74 Million to fund clinical trials | |
| 03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies | May 3, 2022 |
| 16.06.2021 | USD67 million for Alentis Therapeutics | |
| 16.06.2021 | USD67 million for Alentis Therapeutics | Alongside Morningside Venture Investments, Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital joined Alentis’ financing round.
&quo... |
| 01.12.2020 | Noema Pharma raises CHF 54 million in Series A financing round | In 2019, Noema Pharma obtained a seed investment from Sofinnova Partners, a leading European life sciences, venture capital firm based in Paris, London and Milan to embark on a new journey to address orphan neurological disorders characteri... |
| 01.12.2020 | Noema Pharma raises CHF 54 million in Series A financing round | |
| 21.07.2020 | EIT Health helps Tubulis secure €10.7M in funding | Tubulis has raised €10.7 million to advance development of a new generation of antibody-drug conjugates with the support of six investors, including two from the EIT Health Investor Network – BioMedPartners and Seventure Partners.
The EIT ... |
| 10.06.2020 | Additional capital for TOLREMO therapeutics | TOLREMO’s proprietary drug discovery engine enables the identification of novel drug-resistance regulators and the development of small molecule therapies against these promising drug targets. The company’s therapies aim to complement stand... |
| 10.06.2020 | Additional capital for TOLREMO therapeutics | |
| 10.12.2019 | ImmunOs Therapeutics AG raises CHF 15M in Series A Financing | |
| 30.04.2019 | ALENTIS Therapeutics raises CHF 12.5m in a Series A | |
| 12.11.2018 | AMAL Therapeutics finalises CHF 33 million Series B round | |
| 24.09.2018 | TOLREMO raises CHF9 million series A financing round | |
| 13.06.2018 | New CEO and CMO for biotech startups | |
| 02.03.2018 | Amid a boisterous fundraising week, BioMedPartners airs $107M biotech fund | As the VC dollars continue to dominate biopharma headlines this week, Swiss VC group BioMedPartners AG has announced its own windfall: it’s raised an additional $107 million in new money for it’s third venture fund.
The f... |
| 01.03.2018 | BioMedPartners Close Third Healthcare Venture Fund at CHF 100 Million | |
| 05.09.2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund |
| 17.02.2017 | BioMedPartners Raise CHF 75 Million in First Closing of New Healthcare Venture Fund | |
| 27.05.2016 | Aleva Neurotherapeutics Raises USD 18 Million in Series C Financing Round | |
| 04.04.2016 | Anergis Closes CHF 5 Million Financing Round | |
| 02.02.2016 | New partner and investor for Aleva Neurotherapeutics | |
| 23.10.2015 | Sequana Medical AG raises CHF 9 million | |
| 09.01.2015 | Miracor Medical Systems receives additional funding | |
| 08.01.2015 | Miracor Medical Systems Closes €4.5M Extension to Series B Financing | Miracor Medical Systems, a Vienna, Austria-based medical device company, closed a €4.5m extension to its Series B financing.
Backers included new investors BioMedInvest and aws Gründerfonds and existing investors Earlybird Venture Capital, ... |
| 07.01.2015 | Genkyotex Raises CHF 20 Million and Considers IPO | |
| 03.12.2014 | Anergis Closes Series B Financing Round Totaling CHF 14.5 Million | |
| 11.09.2014 | Zukunftsfonds: Parlament gibt grünes Licht | |
| 28.04.2014 | Sequana Medical Raises CHF23M in Series C Financing | Sequana Medical AG, a Zurich, Switzerland-based medical device company with innovative fluid management technologies, has raised CHF23m ($26.2m) in a Series C financing.
The round was led by LSP (Life Science Partners), and co-led by NeoMed... |
| 07.01.2014 | Incubator with six venture-backed spinouts seeks 2014 exit, unveils new sepsis spinout | The six venture-backed spinouts include:
Baronova, a startup trying for weight loss devices that are both non-surgical and non-pharma. The company closed a $27.3 million Series C round in February 2013, which was led by Boston Scientific (B... |
| 06.11.2013 | Delenex Therapeutics closes CHF 7.3 Million Series A3 Financing | |
| 29.10.2013 | Edwards Lifesciences jumps in mitral valve tech race with startup investment | Follow MedCity News on Facebook and Twitter for more updates.
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underser... |
| 29.05.2013 | GSK acquires Okairos AG for EUR 250 mio | |
| 31.05.2012 | Spinelab Raises CHF4.7M in Series C Financing | Spinelab, a Winterthur, Switzerland-based developer of motion preserving stabilization systems for the spine, has raised CHF4.7m (approximately $4.9m) in Series C financing.
The round, which brought the total amount raised by the company to... |
| 31.05.2012 | Spinelab raises CHF 4.7 million in Series C financing round | |
| 10.04.2012 | Aleva Neurotherapeutics Raises CHF 4.0 Million in Series B Financing Round | |
| 01.03.2012 | Anergis Appoints Jacques-François Martin as Chairman of the Board of Directors | |
| - | Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates | Tubulis today announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates (ADCs) and to support the further growth of the company. The ... |
| - | Edwards Lifesciences jumps in mitral valve tech race with startup investment | Edwards Lifesciences (EW) joined BioMedPartners to add $3 million to Middle Peak Medical‘s already oversubscribed Series A round. The funding will go toward commercializing technology to treat mitral valve disease. Lead investors Wellington... |
| - | ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer | ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swis... |
| - | Incubator with six venture-backed spinouts seeks 2014 exit, unveils new sepsis spinout | TheraNova is a San Francisco-based sandbox incubator and capital technology developer for medical devices. With one exception, all the ideas for technology are internally generated, CEO Dr. Daniel Burnett said. That’s led to all its medical... |
| - | AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round | |
